Current Cardioprotective Strategies for the Prevention of Radiation-Induced Cardiotoxicity in Left-Sided Breast Cancer Patients.
cardioprotection
newer radiotherapy methods
radiation-induced cardiotoxicity
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
24 Jun 2023
24 Jun 2023
Historique:
received:
27
03
2023
revised:
11
05
2023
accepted:
20
06
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Breast cancer (BC) is the most common malignancy in females, accounting for the majority of cancer-related deaths worldwide. There is well-established understanding about the effective role of radiotherapy (RT) in BC therapeutic strategies, offering a better local-regional control, prolonged survival, and improved quality of life for patients. However, it has been proven that conventional RT modalities, especially in left-sided BC cases, are unable to avoid the administration of high RT doses to the heart, thus resulting in cardiotoxicity and promoting long-term cardiovascular diseases (CVD). Recent radiotherapeutic techniques, characterized by dosimetric dose restrictions, target volume revision/modifications, an increased awareness of risk factors, and consistent follow-ups, have created an advantageous context for a significant decrease inpost-RT CVD incidence. This review presents the fundamental role of current cardioprotective strategies in the prevention of cardiotoxic effects in left-BCRT. A literature search was conducted up to January 2023 using the Cochrane Central Register of Controlled Trials and PubMed Central databases. Our review refers to new radiotherapeutic techniques carried out on patients after BC surgery. Specifically, a dose evaluation of the heart and left anterior descending coronary artery (LADCA) was pointed out for all the included studies, depending on the implemented RT modality, bed positioning, and internal mammary lymph nodes radiation. Several studies reporting improved heart sparing with new RT techniques in BC patients were searched. In addition to the RT modality, which definitely determines the feasibility of achieving lower doses for the organs at risk (OARs), better target coverage, dose conformity and homogeneity, and the patient's position, characteristics, and anatomy may also affect the evaluated RT dose to the whole heart and its substructures. Modern BC RT techniques seem to enable the administration of lower doses to the OARs without compromising on the target coverage. The analysis of several anatomical parameters and the assessment of cardiac biomarkers potentiate the protective effect of these new irradiation modalities, providing a holistic approach to the radiation-associated risks of cardiac disease for BC patients. Despite technological advances, an inevitable cardiac radiation risk still exists, while adverse cardiac events may be observed even many years after RT. Studies with longer follow-ups are required in order to determine the effectiveness of modern breast RT techniques.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer (BC) is the most common malignancy in females, accounting for the majority of cancer-related deaths worldwide. There is well-established understanding about the effective role of radiotherapy (RT) in BC therapeutic strategies, offering a better local-regional control, prolonged survival, and improved quality of life for patients. However, it has been proven that conventional RT modalities, especially in left-sided BC cases, are unable to avoid the administration of high RT doses to the heart, thus resulting in cardiotoxicity and promoting long-term cardiovascular diseases (CVD). Recent radiotherapeutic techniques, characterized by dosimetric dose restrictions, target volume revision/modifications, an increased awareness of risk factors, and consistent follow-ups, have created an advantageous context for a significant decrease inpost-RT CVD incidence.
AIM
OBJECTIVE
This review presents the fundamental role of current cardioprotective strategies in the prevention of cardiotoxic effects in left-BCRT.
MATERIAL AND METHODS
METHODS
A literature search was conducted up to January 2023 using the Cochrane Central Register of Controlled Trials and PubMed Central databases. Our review refers to new radiotherapeutic techniques carried out on patients after BC surgery. Specifically, a dose evaluation of the heart and left anterior descending coronary artery (LADCA) was pointed out for all the included studies, depending on the implemented RT modality, bed positioning, and internal mammary lymph nodes radiation.
RESULTS
RESULTS
Several studies reporting improved heart sparing with new RT techniques in BC patients were searched. In addition to the RT modality, which definitely determines the feasibility of achieving lower doses for the organs at risk (OARs), better target coverage, dose conformity and homogeneity, and the patient's position, characteristics, and anatomy may also affect the evaluated RT dose to the whole heart and its substructures.
CONCLUSIONS
CONCLUSIONS
Modern BC RT techniques seem to enable the administration of lower doses to the OARs without compromising on the target coverage. The analysis of several anatomical parameters and the assessment of cardiac biomarkers potentiate the protective effect of these new irradiation modalities, providing a holistic approach to the radiation-associated risks of cardiac disease for BC patients. Despite technological advances, an inevitable cardiac radiation risk still exists, while adverse cardiac events may be observed even many years after RT. Studies with longer follow-ups are required in order to determine the effectiveness of modern breast RT techniques.
Identifiants
pubmed: 37511651
pii: jpm13071038
doi: 10.3390/jpm13071038
pmc: PMC10381791
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Cancer Res Ther. 2017 Apr-Jun;13(2):186-192
pubmed: 28643731
Chemotherapy. 2020;65(3-4):65-76
pubmed: 33049738
Cancers (Basel). 2021 Aug 25;13(17):
pubmed: 34503097
Radiother Oncol. 2022 Dec;177:46-52
pubmed: 36309152
Radiat Oncol. 2020 May 24;15(1):117
pubmed: 32448164
Cancers (Basel). 2021 Apr 04;13(7):
pubmed: 33916644
Sci Rep. 2022 Aug 4;12(1):13377
pubmed: 35927418
Radiother Oncol. 2019 Mar;132:250-256
pubmed: 30414757
Strahlenther Onkol. 2021 Apr;197(4):317-331
pubmed: 33416915
Eur J Heart Fail. 2020 Nov;22(11):1966-1983
pubmed: 33006257
JACC CardioOncol. 2021 Sep 21;3(3):343-359
pubmed: 34604796
Trends Cardiovasc Med. 2020 Jan;30(1):22-28
pubmed: 30745071
Circ J. 2009 Dec;73(12):2294-9
pubmed: 19838000
Oxid Med Cell Longev. 2020 Mar 1;2020:3579143
pubmed: 32190171
Anticancer Res. 2021 Mar;41(3):1529-1538
pubmed: 33788746
Breast Care (Basel). 2018 Jul;13(3):168-172
pubmed: 30069176
Anticancer Res. 2020 May;40(5):3003-3009
pubmed: 32366455
J Pers Med. 2021 May 13;11(5):
pubmed: 34068305
Isr Med Assoc J. 2018 Sep;20(9):582-583
pubmed: 30221874
Br J Radiol. 2020 Apr;93(1108):20190792
pubmed: 31939310
Radiat Oncol. 2020 Aug 20;15(1):201
pubmed: 32819449
Circulation. 2004 Dec 21;110(25):3808-14
pubmed: 15583080
Cancers (Basel). 2022 Jul 18;14(14):
pubmed: 35884538
Cancer Detect Prev. 2004;28(6):399-408
pubmed: 15582263
Medicina (Kaunas). 2019 May 09;55(5):
pubmed: 31075882
Cancer Manag Res. 2014 Apr 16;6:191-203
pubmed: 24790468
Cancers (Basel). 2022 Aug 20;14(16):
pubmed: 36011025
Front Cardiovasc Med. 2022 Jul 28;9:887705
pubmed: 35966531
Curr Cardiol Rep. 2016 Oct;18(10):99
pubmed: 27566332
Am J Cardiol. 2013 Nov 15;112(10):1688-96
pubmed: 24012026
Breast Cancer (Dove Med Press). 2022 Jul 20;14:175-186
pubmed: 35899145
Radiat Oncol. 2016 Oct 26;11(1):143
pubmed: 27784326
Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):891-9
pubmed: 14529796
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):268-76
pubmed: 25968824
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Curr Probl Cancer. 2020 Feb;44(1):100488
pubmed: 31235186
Am J Cancer Res. 2019 May 01;9(5):1017-1026
pubmed: 31218109
Radiat Oncol. 2014 Feb 26;9:66
pubmed: 24571913
J Clin Oncol. 2017 May 20;35(15):1641-1649
pubmed: 28319436
Int J Cancer. 2020 Sep 1;147(5):1437-1449
pubmed: 32022260
J Appl Clin Med Phys. 2018 Jul;19(4):195-204
pubmed: 29927027
Radiother Oncol. 2010 Aug;96(2):178-84
pubmed: 20561695
Breast Care (Basel). 2015 Apr;10(2):131-5
pubmed: 26195942
Tech Innov Patient Support Radiat Oncol. 2021 Dec 16;20:64-65
pubmed: 34988301
Pract Radiat Oncol. 2019 Jul - Aug;9(4):239-247
pubmed: 30914270
Tech Innov Patient Support Radiat Oncol. 2021 Mar 01;17:25-31
pubmed: 33681484
Medicine (Baltimore). 2021 May 21;100(20):e26000
pubmed: 34011096
J Clin Med. 2020 Jun 02;9(6):
pubmed: 32498398
Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):836-44
pubmed: 26530752
Rep Pract Oncol Radiother. 2022 Oct 31;27(5):797-808
pubmed: 36523797
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):94-100
pubmed: 19304405
Theranostics. 2021 Sep 9;11(19):9376-9396
pubmed: 34646376
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211048706
pubmed: 34657495
Radiat Oncol. 2021 Sep 6;16(1):171
pubmed: 34488817
Front Oncol. 2022 Apr 21;12:845037
pubmed: 35530354
Radiat Oncol. 2015 Jul 10;10:141
pubmed: 26159409
Radiol Oncol. 2021 Jan 29;55(2):212-220
pubmed: 33600676
S Afr J Surg. 2019 Sep;57(3):56
pubmed: 31392868
Breast Care (Basel). 2021 Aug;16(4):358-367
pubmed: 34602941
Radiat Oncol J. 2020 Sep;38(3):181-188
pubmed: 33012146
Phys Med Biol. 2021 Nov 22;66(23):
pubmed: 34736246
Radiat Oncol. 2015 Dec 30;10:264
pubmed: 26715382
Medicine (Baltimore). 2019 Jul;98(29):e16507
pubmed: 31335723
Acta Oncol. 2014 Jan;53(1):58-64
pubmed: 23544358
Anticancer Res. 2019 Apr;39(4):1667-1673
pubmed: 30952705
Exp Gerontol. 2022 Apr;160:111706
pubmed: 35085707
Front Oncol. 2018 Apr 04;8:87
pubmed: 29670854
Adv Radiat Oncol. 2019 Jan 30;4(2):246-252
pubmed: 31011669
Cancer Radiother. 2016 Sep;20 Suppl:S139-46
pubmed: 27522187
Circ Cardiovasc Imaging. 2012 Sep 1;5(5):596-603
pubmed: 22744937
Br J Radiol. 2011 Nov;84(1007):967-96
pubmed: 22011829
Cureus. 2020 Mar 12;12(3):e7247
pubmed: 32292662
Eur J Breast Health. 2021 Jun 24;17(3):247-252
pubmed: 34263152
Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):980-7
pubmed: 19251085
Strahlenther Onkol. 2019 Jan;195(1):1-12
pubmed: 30310926
Acta Oncol. 2018 Jan;57(1):113-119
pubmed: 29205080
Radiat Oncol. 2018 May 31;13(1):103
pubmed: 29855325
J Am Heart Assoc. 2021 Apr 6;10(7):e019476
pubmed: 33749308
Eur Heart J. 2022 Nov 1;43(41):4229-4361
pubmed: 36017568
Radiother Oncol. 2018 Mar;126(3):487-492
pubmed: 29373194
Cancer Res Treat. 2019 Oct;51(4):1370-1379
pubmed: 30776884
Radiat Oncol. 2015 Apr 10;10:84
pubmed: 25884950
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825
J Appl Clin Med Phys. 2023 Jan;24(1):e13755
pubmed: 35993318
Pol Merkur Lekarski. 2019 May 27;46(275):195-204
pubmed: 31152530